Cannabinoid receptor 1 (CNR1) Antibody

Este producto es parte de CNR - Cannabinoid Receptor
Product Graph
299€ (50 µl)

Por favor contáctenos para obtener información detallada sobre el precio y disponibilidad.

935106861
info@markelab.com
name
Cannabinoid receptor 1 (CNR1) Antibody
category
Primary Antibodies
provider
Abbexa
reference
abx349890
tested applications
ELISA

Description

Cannabinoid receptor 1 (CNR1) Antibody is a Recombinant Human Monoclonal antibody for the detection of Human CNR1.

Documents del producto

Instrucciones
Data sheet
Descargar

Product specifications

Category
Primary Antibodies
Immunogen Target
Cannabinoid receptor 1 (CNR1)
Host
Human
Reactivity
Human
Recommended Dilution
Optimal dilutions/concentrations should be determined by the end user.
Clonality
Monoclonal
Conjugation
Unconjugated
Isotype
IgG4 (S228P)
Expression
Recombinant
Purification
Purified by affinity chromatography.
Size 1
50 µl
Size 2
100 µl
Form
Liquid
Tested Applications
ELISA
Buffer
0.01 M PBS, pH 7.4, 0.03% Proclin-300 and 50% glycerol.
Availability
Shipped within 5-10 working days.
Storage
Aliquot and store at -20°C. Avoid repeated freeze/thaw cycles.
Dry Ice
No
UniProt ID
P21554
Alias
CNR1,THC receptor,CB-R,Cann6,SKR6R,CB1R,Cann7,CB1, CB1A, CB1K5,CNR
Background
Antibody anti-CNR1
Status
RUO

Descripción

Cannabinoid Receptor 1 (CNR1), commonly known as CB1, is one of the two primary receptors of the endocannabinoid system (ECS), a lipid signaling system that regulates homeostasis and diverse physiological processes. CB1 is predominantly expressed in the central nervous system (CNS), including regions like the hippocampus, cerebellum, and basal ganglia, where it modulates synaptic transmission and neuronal activity. CB1 interacts with endocannabinoids like anandamide (AEA) and 2-arachidonoylglycerol (2-AG), as well as exogenous cannabinoids like tetrahydrocannabinol (THC), the psychoactive compound in cannabis. Through this interaction, CB1 plays a key role in regulating pain perception, mood, appetite, memory, and motor control. In the periphery, CB1 expression in tissues such as the liver, adipose tissue, and pancreas contributes to energy metabolism, glucose homeostasis, and lipid storage, linking CB1 to obesity and metabolic disorders. Overactivation of CB1 signaling is associated with conditions like addiction, anxiety, and depression, as well as non-alcoholic fatty liver disease (NAFLD) and insulin resistance. CB1 antagonists, such as rimonabant, have been explored for treating obesity and metabolic syndrome, although their psychiatric side effects limit widespread use. The ECS, particularly CB1, continues to be a focus of intense research for developing safer therapeutics targeting pain, neurological disorders, and psychiatric conditions, including post-traumatic stress disorder (PTSD) and epilepsy.

Related Products

EH2848

Human CNR1 (Cannabinoid Receptor 1, Brain) ELISA Kit

Ver Producto
EM0936

Mouse CNR1 (Cannabinoid Receptor 1, Brain) ELISA Kit

Ver Producto
FNab01244

CNR1 antibody

Ver Producto